mannitol | Mannitol infusion solution 150mg / ml 400 ml vials 1pc.

Packing

Bottle 400 ml.

Pharmacological action

Mannitol - osmotic diuretic. By increasing the osmotic pressure of the plasma and filtering without subsequent reabsorption leads to the retention of water in the tubules and an increase in urine volume. Increasing the osmolarity of blood plasma, causes the movement of fluid from tissues (in particular the eyeball, brain) into the vascular bed. Does not affect glomerular filtration. Diuresis is accompanied by a moderate increase in natriuresis without a significant effect on the excretion of potassium ions. The diuretic effect is the higher, the greater the concentration (dose). Ineffective in violation of the filtration function of the kidneys, as well as azotemia in patients with cirrhosis and ascites. It causes an increase in bcc.

Indications

cerebral edema

intracranial hypertension (with renal or renal hepatic insufficiency)

oliguria in acute renal or renal hepatic insufficiency with preserved renal filtration ability (as part of combination therapy) after acute reduction of acute postoperative distress poisoning with

barbiturates and salicylates for the prevention of hemolysis in operations with extracorporeal circulation to prevent renal ischemia to and related acute renal failure.

Use during pregnancy and lactation

During pregnancy and lactation, the drug is used only in cases where the intended benefits to the mother outweigh the possible risk to the fetus or baby.

Composition

In 1 liter of solution contains:

Active ingredient: mannitol (mannitol) 150 g

Excipients: sodium chloride 9 g, water for injection up to 1 l.

Dosage and administration

Intravenously, slowly, in a stream or drip.

The prophylactic dose is 0.5 g / kg, the therapeutic dose is 1–1.5 g / kg, the daily dose should not exceed 140–180 g.

Before administration, the drug should be heated to a temperature of 37 РC (can be done in a water bath).

In operations with cardiopulmonary bypass, the drug is injected into the device at a dose of 20–40 g immediately before the start of perfusion.

Patients with oliguria should first administer an intravenous drip test dose (200 mg / kg) for 3-5 minutes. If after this within 2-3 hours there will be no increase in the rate of urine output to 30-50 ml / h, you should refrain from further administration of the drug.

Side effects

Dehydration (dry skin, dyspepsia, myasthenia gravis, cramps, dry mouth, thirst, hallucinations, decreased blood pressure), impaired water-electrolyte metabolism (increased bcc, hyponatremia rarely - hyperkalemia).

Rarely - tachycardia, chest pain, thrombophlebitis, skin rash.

Drug Interaction

Increased toxicity of cardiac glycosides (associated with hypokalemia).

Storage Conditions

At 18–25 РC.

Shelf life

2 years

Terms and conditions

prescription

Lek rstvennaya form

infusion solution

Possible Product Names

Mannitol 15% solution d / inf. 400ml Booth. X1 B M (R)

Mannitol solution d / inf. 15% fl. 400ml N1 (for hospitals) Russia

MANNIT R-D ​​D / INF. 150MG / ML FL. 400ML

Mannitol solution for infusion 15% 400 ml

Mannitol solution for infusion 150 mg / ml vials 400 ml 1pc.